4.03 USD
+0.06 (+1.51%)
4.03 USD
0 (0%)
VYGR gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 533 industry peers in the Biotechnology industry. VYGR has a great financial health rating, but its profitability evaluates not so good. VYGR has a expensive valuation and it also scores bad on growth.
1. Profitability
1.1 Basic Checks
VYGR had negative earnings in the past year.
In the past year VYGR has reported a negative cash flow from operations.
The reported net income has been mixed in the past 5 years: VYGR reported negative net income in multiple years.
In the past 5 years VYGR reported 4 times negative operating cash flow.
1.2 Ratios
The Return On Assets of VYGR (-43.97%) is comparable to the rest of the industry.
The Return On Equity of VYGR (-57.67%) is better than 62.10% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -43.97% | ||
| ROE | -57.67% | ||
| ROIC | N/A |
ROA(3y)-2.66%
ROA(5y)-6.13%
ROE(3y)-14.78%
ROE(5y)-19.08%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin and Operating Margin and Gross Margin are not available for VYGR so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
VYGR does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, VYGR has more shares outstanding
Compared to 5 years ago, VYGR has more shares outstanding
VYGR has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
VYGR has an Altman-Z score of -0.80. This is a bad value and indicates that VYGR is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -0.80, VYGR is in line with its industry, outperforming 57.41% of the companies in the same industry.
There is no outstanding debt for VYGR. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -0.8 |
ROIC/WACCN/A
WACC8.65%
2.3 Liquidity
VYGR has a Current Ratio of 6.19. This indicates that VYGR is financially healthy and has no problem in meeting its short term obligations.
VYGR has a better Current ratio (6.19) than 64.73% of its industry peers.
A Quick Ratio of 6.19 indicates that VYGR has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 6.19, VYGR is in the better half of the industry, outperforming 66.04% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 6.19 | ||
| Quick Ratio | 6.19 |
3. Growth
3.1 Past
VYGR shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -404.23%.
Looking at the last year, VYGR shows a very negative growth in Revenue. The Revenue has decreased by -80.88% in the last year.
Measured over the past years, VYGR shows a decrease in Revenue. The Revenue has been decreasing by -5.18% on average per year.
EPS 1Y (TTM)-404.23%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-193.75%
Revenue 1Y (TTM)-80.88%
Revenue growth 3Y28.85%
Revenue growth 5Y-5.18%
Sales Q2Q%-45.73%
3.2 Future
The Earnings Per Share is expected to decrease by -4.08% on average over the next years.
The Revenue is expected to grow by 1.98% on average over the next years.
EPS Next Y-90.87%
EPS Next 2Y-15.79%
EPS Next 3Y-8.06%
EPS Next 5Y-4.08%
Revenue Next Year-66.69%
Revenue Next 2Y-16.94%
Revenue Next 3Y-9.05%
Revenue Next 5Y1.98%
3.3 Evolution
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for VYGR. In the last year negative earnings were reported.
Also next year VYGR is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
VYGR's earnings are expected to decrease with -8.06% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-15.79%
EPS Next 3Y-8.06%
5. Dividend
5.1 Amount
No dividends for VYGR!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
4.03
+0.06 (+1.51%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners60.07%
Inst Owner Change-9.19%
Ins Owners0.88%
Ins Owner Change-0.21%
Market Cap223.54M
Revenue(TTM)31.32M
Net Income(TTM)-126.78M
Analysts87.78
Price Target15.3 (279.65%)
Short Float %6.69%
Short Ratio4.5
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)2.56%
Min EPS beat(2)-6.33%
Max EPS beat(2)11.46%
EPS beat(4)1
Avg EPS beat(4)-17.11%
Min EPS beat(4)-57.86%
Max EPS beat(4)11.46%
EPS beat(8)5
Avg EPS beat(8)79.25%
EPS beat(12)8
Avg EPS beat(12)75.9%
EPS beat(16)10
Avg EPS beat(16)73.9%
Revenue beat(2)1
Avg Revenue beat(2)9.1%
Min Revenue beat(2)-48.55%
Max Revenue beat(2)66.75%
Revenue beat(4)1
Avg Revenue beat(4)-24.46%
Min Revenue beat(4)-62.87%
Max Revenue beat(4)66.75%
Revenue beat(8)5
Avg Revenue beat(8)80.35%
Revenue beat(12)8
Avg Revenue beat(12)85.04%
Revenue beat(16)10
Avg Revenue beat(16)78%
PT rev (1m)-4.26%
PT rev (3m)-4.26%
EPS NQ rev (1m)-4.52%
EPS NQ rev (3m)-3.76%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)-4.12%
Revenue NQ rev (3m)-7.25%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 7.14 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 1.02 | ||
| P/tB | 1.02 | ||
| EV/EBITDA | N/A |
EPS(TTM)-2.16
EYN/A
EPS(NY)-1.51
Fwd EYN/A
FCF(TTM)-2.14
FCFYN/A
OCF(TTM)-2.1
OCFYN/A
SpS0.56
BVpS3.96
TBVpS3.96
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -43.97% | ||
| ROE | -57.67% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-2.66%
ROA(5y)-6.13%
ROE(3y)-14.78%
ROE(5y)-19.08%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.11
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 52.83% | ||
| Cap/Sales | 6.79% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 6.19 | ||
| Quick Ratio | 6.19 | ||
| Altman-Z | -0.8 |
F-Score2
WACC8.65%
ROIC/WACCN/A
Cap/Depr(3y)62.66%
Cap/Depr(5y)107.17%
Cap/Sales(3y)3.93%
Cap/Sales(5y)4.63%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-404.23%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-193.75%
EPS Next Y-90.87%
EPS Next 2Y-15.79%
EPS Next 3Y-8.06%
EPS Next 5Y-4.08%
Revenue 1Y (TTM)-80.88%
Revenue growth 3Y28.85%
Revenue growth 5Y-5.18%
Sales Q2Q%-45.73%
Revenue Next Year-66.69%
Revenue Next 2Y-16.94%
Revenue Next 3Y-9.05%
Revenue Next 5Y1.98%
EBIT growth 1Y-1280.72%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-74.77%
EBIT Next 3Y-8.22%
EBIT Next 5Y-16.3%
FCF growth 1Y-238.05%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-230.43%
OCF growth 3YN/A
OCF growth 5YN/A
VOYAGER THERAPEUTICS INC / VYGR FAQ
What is the fundamental rating for VYGR stock?
ChartMill assigns a fundamental rating of 3 / 10 to VYGR.
Can you provide the valuation status for VOYAGER THERAPEUTICS INC?
ChartMill assigns a valuation rating of 0 / 10 to VOYAGER THERAPEUTICS INC (VYGR). This can be considered as Overvalued.
What is the profitability of VYGR stock?
VOYAGER THERAPEUTICS INC (VYGR) has a profitability rating of 1 / 10.
What is the financial health of VOYAGER THERAPEUTICS INC (VYGR) stock?
The financial health rating of VOYAGER THERAPEUTICS INC (VYGR) is 7 / 10.
What is the earnings growth outlook for VOYAGER THERAPEUTICS INC?
The Earnings per Share (EPS) of VOYAGER THERAPEUTICS INC (VYGR) is expected to decline by -90.87% in the next year.